a public good project by the
Synthesis
Company
of California

© 2026

April Chen | doi.page

0 works0 citations0 h-index

April Chen

AstraZeneca (South Korea)(KR)AstraZeneca (Brazil)(BR)AstraZeneca (United States)(US)

Publications by Year

Research Areas

Antibiotics Pharmacokinetics and Efficacy, Cancer Mechanisms and Therapy, Antibiotic Resistance in Bacteria, Liver physiology and pathology, Quinazolinone synthesis and applications

Most-Cited Works

→ Discovery and Optimization of Triazolopyridazines as Potent and Selective Inhibitors of the c-Met Kinase(2008)139 cited
→ Rational design of a new antibiotic class for drug-resistant infections(2021)137 cited
→ Discovery of a Potent, Selective, and Orally Bioavailable c-Met Inhibitor: 1-(2-Hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458)(2008)94 cited
→ Pharmacodynamic Profiling of a Siderophore-Conjugated Monocarbam in Pseudomonas aeruginosa: Assessing the Risk for Resistance and Attenuated Efficacy(2015)76 cited
→ Reversibility of Covalent, Broad-Spectrum Serine β-Lactamase Inhibition by the Diazabicyclooctenone ETX2514(2017)59 cited
→ Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases(2020)59 cited

→ Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors(2009)56 cited

→ Identification of a Novel Recepteur d'Origine Nantais/c-Met Small-Molecule Kinase Inhibitor with Antitumor Activity In vivo(2008)55 cited

→ Identification of a Potent, State-Dependent Inhibitor of Nav1.7 with Oral Efficacy in the Formalin Model of Persistent Pain(2011)54 cited

→ Relationship between Passive Permeability, Efflux, and Predictability of Clearance from In Vitro Metabolic Intrinsic Clearance(2009)44 cited